RAC Beta SerineThreonine Protein Kinase - Pipeline Review, H2 2019
RAC Beta SerineThreonine Protein Kinase - Pipeline Review, H2 2019
SUMMARY
According to the recently published report 'RAC Beta SerineThreonine Protein Kinase - Pipeline Review, H2 2019'; RAC Beta Serine/Threonine Protein Kinase (Protein Kinase Akt 2 or Protein Kinase B Beta or RAC PK Beta or AKT2 or EC 2.7.11.1) pipeline Target constitutes close to 9 molecules.
RAC Beta Serine/Threonine Protein Kinase (Protein Kinase Akt 2 or Protein Kinase B Beta or RAC PK Beta or AKT2 or EC 2.7.11.1) - RAC-beta serine/threonine-protein kinase is an enzyme encoded by the AKT2 gene. It plays a role as key modulator of the AKT-mTOR signaling pathway controlling the tempo of the process of newborn neurons integration during adult neurogenesis, including correct neuron positioning, dendritic development and synapse formation. AKT2 is also specifically involved in skeletal muscle differentiation, one of its substrates in this process being ANKRD2.
The report 'RAC Beta SerineThreonine Protein Kinase - Pipeline Review, H2 2019' outlays comprehensive information on the RAC Beta Serine/Threonine Protein Kinase (Protein Kinase Akt 2 or Protein Kinase B Beta or RAC PK Beta or AKT2 or EC 2.7.11.1) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type; that are being developed by Companies / Universities.
It also reviews key players involved in RAC Beta Serine/Threonine Protein Kinase (Protein Kinase Akt 2 or Protein Kinase B Beta or RAC PK Beta or AKT2 or EC 2.7.11.1) targeted therapeutics development with respective active and dormant or discontinued projects. Currently, The molecules developed by companies in Phase III, Phase II, Phase I and Preclinical stages are 1, 6, 1 and 1 respectively. Report covers products from therapy areas Oncology, Hematological Disorders, Non Malignant Disorders and Undisclosed which include indications Endometrial Cancer, Non-Small Cell Lung Cancer, Triple-Negative Breast Cancer (TNBC), Ovarian Cancer, Fallopian Tube Cancer, Melanoma, Metastatic Breast Cancer, Peritoneal Cancer, Prostate Cancer, Refractory Acute Myeloid Leukemia, Refractory Multiple Myeloma, Relapsed Acute Myeloid Leukemia, Relapsed Multiple Myeloma, Small-Cell Lung Cancer, Solid Tumor, Anal Cancer, Brain Cancer, Cervical Cancer, Colorectal Cancer, Esophageal Cancer, Gastrointestinal Stromal Tumor (GIST), Glioblastoma Multiforme (GBM), Head And Neck Cancer Squamous Cell Carcinoma, Hepatocellular Carcinoma, Leukemia, Li-Fraumeni Syndrome (LFS), Lymphoma, Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer, Pancreatic Cancer, Proteus Syndrome, Sickle Cell Disease, Thymoma (Thymic Epithelial Tumor), Unspecified Rare Disease and Uterine Cancer.
SCOPE
SUMMARY
According to the recently published report 'RAC Beta SerineThreonine Protein Kinase - Pipeline Review, H2 2019'; RAC Beta Serine/Threonine Protein Kinase (Protein Kinase Akt 2 or Protein Kinase B Beta or RAC PK Beta or AKT2 or EC 2.7.11.1) pipeline Target constitutes close to 9 molecules.
RAC Beta Serine/Threonine Protein Kinase (Protein Kinase Akt 2 or Protein Kinase B Beta or RAC PK Beta or AKT2 or EC 2.7.11.1) - RAC-beta serine/threonine-protein kinase is an enzyme encoded by the AKT2 gene. It plays a role as key modulator of the AKT-mTOR signaling pathway controlling the tempo of the process of newborn neurons integration during adult neurogenesis, including correct neuron positioning, dendritic development and synapse formation. AKT2 is also specifically involved in skeletal muscle differentiation, one of its substrates in this process being ANKRD2.
The report 'RAC Beta SerineThreonine Protein Kinase - Pipeline Review, H2 2019' outlays comprehensive information on the RAC Beta Serine/Threonine Protein Kinase (Protein Kinase Akt 2 or Protein Kinase B Beta or RAC PK Beta or AKT2 or EC 2.7.11.1) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type; that are being developed by Companies / Universities.
It also reviews key players involved in RAC Beta Serine/Threonine Protein Kinase (Protein Kinase Akt 2 or Protein Kinase B Beta or RAC PK Beta or AKT2 or EC 2.7.11.1) targeted therapeutics development with respective active and dormant or discontinued projects. Currently, The molecules developed by companies in Phase III, Phase II, Phase I and Preclinical stages are 1, 6, 1 and 1 respectively. Report covers products from therapy areas Oncology, Hematological Disorders, Non Malignant Disorders and Undisclosed which include indications Endometrial Cancer, Non-Small Cell Lung Cancer, Triple-Negative Breast Cancer (TNBC), Ovarian Cancer, Fallopian Tube Cancer, Melanoma, Metastatic Breast Cancer, Peritoneal Cancer, Prostate Cancer, Refractory Acute Myeloid Leukemia, Refractory Multiple Myeloma, Relapsed Acute Myeloid Leukemia, Relapsed Multiple Myeloma, Small-Cell Lung Cancer, Solid Tumor, Anal Cancer, Brain Cancer, Cervical Cancer, Colorectal Cancer, Esophageal Cancer, Gastrointestinal Stromal Tumor (GIST), Glioblastoma Multiforme (GBM), Head And Neck Cancer Squamous Cell Carcinoma, Hepatocellular Carcinoma, Leukemia, Li-Fraumeni Syndrome (LFS), Lymphoma, Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer, Pancreatic Cancer, Proteus Syndrome, Sickle Cell Disease, Thymoma (Thymic Epithelial Tumor), Unspecified Rare Disease and Uterine Cancer.
SCOPE
- The report provides a snapshot of the global therapeutic landscape for RAC Beta Serine/Threonine Protein Kinase (Protein Kinase Akt 2 or Protein Kinase B Beta or RAC PK Beta or AKT2 or EC 2.7.11.1)
- The report reviews RAC Beta Serine/Threonine Protein Kinase (Protein Kinase Akt 2 or Protein Kinase B Beta or RAC PK Beta or AKT2 or EC 2.7.11.1) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in RAC Beta Serine/Threonine Protein Kinase (Protein Kinase Akt 2 or Protein Kinase B Beta or RAC PK Beta or AKT2 or EC 2.7.11.1) targeted therapeutics and enlists all their major and minor projects
- The report assesses RAC Beta Serine/Threonine Protein Kinase (Protein Kinase Akt 2 or Protein Kinase B Beta or RAC PK Beta or AKT2 or EC 2.7.11.1) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news and deals related to RAC Beta Serine/Threonine Protein Kinase (Protein Kinase Akt 2 or Protein Kinase B Beta or RAC PK Beta or AKT2 or EC 2.7.11.1) targeted therapeutics
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand the targeted therapy areas and indications for RAC Beta Serine/Threonine Protein Kinase (Protein Kinase Akt 2 or Protein Kinase B Beta or RAC PK Beta or AKT2 or EC 2.7.11.1)
- Identify the use of drugs for target identification and drug repurposing
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding RAC Beta Serine/Threonine Protein Kinase (Protein Kinase Akt 2 or Protein Kinase B Beta or RAC PK Beta or AKT2 or EC 2.7.11.1) development landscape
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
Introduction
Global Markets Direct Report Coverage
RAC Beta Serine/Threonine Protein Kinase (Protein Kinase Akt 2 or Protein Kinase B Beta or RAC PK Beta or AKT2 or EC 2.7.11.1) - Overview
RAC Beta Serine/Threonine Protein Kinase (Protein Kinase Akt 2 or Protein Kinase B Beta or RAC PK Beta or AKT2 or EC 2.7.11.1) - Therapeutics Development
Products under Development by Stage of Development
Products under Development by Therapy Area
Products under Development by Indication
Products under Development by Companies
RAC Beta Serine/Threonine Protein Kinase (Protein Kinase Akt 2 or Protein Kinase B Beta or RAC PK Beta or AKT2 or EC 2.7.11.1) - Therapeutics Assessment
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
RAC Beta Serine/Threonine Protein Kinase (Protein Kinase Akt 2 or Protein Kinase B Beta or RAC PK Beta or AKT2 or EC 2.7.11.1) - Companies Involved in Therapeutics Development
ArQule Inc
AstraZeneca Plc
Bayer AG
Cotinga Pharmaceuticals Inc
Laekna Therapeutics Shanghai Co Ltd
Merck & Co Inc
Novartis AG
RAC Beta Serine/Threonine Protein Kinase (Protein Kinase Akt 2 or Protein Kinase B Beta or RAC PK Beta or AKT2 or EC 2.7.11.1) - Drug Profiles
ARQ-751 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
BAY-1125976 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
capivasertib - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
COTI-2 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
miransertib mesylate - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
MK-2206 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
MK-2206 + selumetinib sulfate - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
trametinib dimethyl sulfoxide + uprosertib - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
uprosertib - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
RAC Beta Serine/Threonine Protein Kinase (Protein Kinase Akt 2 or Protein Kinase B Beta or RAC PK Beta or AKT2 or EC 2.7.11.1) - Dormant Products
RAC Beta Serine/Threonine Protein Kinase (Protein Kinase Akt 2 or Protein Kinase B Beta or RAC PK Beta or AKT2 or EC 2.7.11.1) - Product Development Milestones
Featured News & Press Releases
Oct 29, 2019: ArQule presents recent data on ARQ 751 at the 2019 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
Oct 21, 2019: ArQule announces preclinical data demonstrating potential of Miransertib (ARQ 092) to treat PIK3CA-driven vascular malformations at 2019 ASHG Annual Meeting
Oct 16, 2019: ArQule announces presentations on ARQ 751 at the 2019 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
Oct 08, 2019: ArQule to Present Preclinical Data on Miransertib for the Treatment of Vascular Malformations at the 2019 American Society of Human Genetics (ASHG) Annual Meeting
Oct 02, 2019: ArQule announces first patient dosed in registrational MOSIAC trial of Miransertib for the treatment of Proteus Syndrome and PIK3CA-related Overgrowth Spectrum
Jul 18, 2019: Cotinga Pharmaceuticals releases additional interim data of phase 1b/2a combination trial of COTI-2 in solid tumors
Jun 27, 2019: Cotinga Pharmaceuticals doses first patient in third cohort of phase 1b/2a combination trial of COTI-2 in Solid Tumors
Jun 17, 2019: ArQule announces preliminary results from its phase 1/2 study of Miransertib (ARQ 092), in Patients with PIK3CA-related Overgrowth Spectrum (PROS) and Proteus syndrome (PS) in an oral presentation at the European Society of Human Genetics Conference
Jun 10, 2019: ArQule announces oral presentation for its Pan-AKT inhibitor, miransertib, at the 2019 European Society of Human Genetics (ESHG) Conference
Jun 05, 2019: Cotinga Pharmaceuticals announces initiation of next cohort of phase 1b/2a combination trial of COTI-2 in solid tumors
May 08, 2019: Cotinga Pharmaceuticals releases early interim data of phase 1b/2a combination trial of COTI-2 in solid tumors
Mar 19, 2019: Cotinga Pharmacueticals provides scientific and business update at annual general meeting and announces unit offering
Feb 26, 2019: Cotinga Pharmaceuticals doses first patient in second cohort of phase 1b/2a combination trial of COTI-2 in Solid Tumors
Feb 25, 2019: ArQule announces publication of clinical data with Miransertib in Proteus syndrome
Jan 29, 2019: Cotinga Pharmaceuticals doses cohort 1 patients with combination therapy in phase 1b/2a trial of COTI-2
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
Global Markets Direct Report Coverage
RAC Beta Serine/Threonine Protein Kinase (Protein Kinase Akt 2 or Protein Kinase B Beta or RAC PK Beta or AKT2 or EC 2.7.11.1) - Overview
RAC Beta Serine/Threonine Protein Kinase (Protein Kinase Akt 2 or Protein Kinase B Beta or RAC PK Beta or AKT2 or EC 2.7.11.1) - Therapeutics Development
Products under Development by Stage of Development
Products under Development by Therapy Area
Products under Development by Indication
Products under Development by Companies
RAC Beta Serine/Threonine Protein Kinase (Protein Kinase Akt 2 or Protein Kinase B Beta or RAC PK Beta or AKT2 or EC 2.7.11.1) - Therapeutics Assessment
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
RAC Beta Serine/Threonine Protein Kinase (Protein Kinase Akt 2 or Protein Kinase B Beta or RAC PK Beta or AKT2 or EC 2.7.11.1) - Companies Involved in Therapeutics Development
ArQule Inc
AstraZeneca Plc
Bayer AG
Cotinga Pharmaceuticals Inc
Laekna Therapeutics Shanghai Co Ltd
Merck & Co Inc
Novartis AG
RAC Beta Serine/Threonine Protein Kinase (Protein Kinase Akt 2 or Protein Kinase B Beta or RAC PK Beta or AKT2 or EC 2.7.11.1) - Drug Profiles
ARQ-751 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
BAY-1125976 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
capivasertib - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
COTI-2 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
miransertib mesylate - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
MK-2206 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
MK-2206 + selumetinib sulfate - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
trametinib dimethyl sulfoxide + uprosertib - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
uprosertib - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
RAC Beta Serine/Threonine Protein Kinase (Protein Kinase Akt 2 or Protein Kinase B Beta or RAC PK Beta or AKT2 or EC 2.7.11.1) - Dormant Products
RAC Beta Serine/Threonine Protein Kinase (Protein Kinase Akt 2 or Protein Kinase B Beta or RAC PK Beta or AKT2 or EC 2.7.11.1) - Product Development Milestones
Featured News & Press Releases
Oct 29, 2019: ArQule presents recent data on ARQ 751 at the 2019 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
Oct 21, 2019: ArQule announces preclinical data demonstrating potential of Miransertib (ARQ 092) to treat PIK3CA-driven vascular malformations at 2019 ASHG Annual Meeting
Oct 16, 2019: ArQule announces presentations on ARQ 751 at the 2019 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
Oct 08, 2019: ArQule to Present Preclinical Data on Miransertib for the Treatment of Vascular Malformations at the 2019 American Society of Human Genetics (ASHG) Annual Meeting
Oct 02, 2019: ArQule announces first patient dosed in registrational MOSIAC trial of Miransertib for the treatment of Proteus Syndrome and PIK3CA-related Overgrowth Spectrum
Jul 18, 2019: Cotinga Pharmaceuticals releases additional interim data of phase 1b/2a combination trial of COTI-2 in solid tumors
Jun 27, 2019: Cotinga Pharmaceuticals doses first patient in third cohort of phase 1b/2a combination trial of COTI-2 in Solid Tumors
Jun 17, 2019: ArQule announces preliminary results from its phase 1/2 study of Miransertib (ARQ 092), in Patients with PIK3CA-related Overgrowth Spectrum (PROS) and Proteus syndrome (PS) in an oral presentation at the European Society of Human Genetics Conference
Jun 10, 2019: ArQule announces oral presentation for its Pan-AKT inhibitor, miransertib, at the 2019 European Society of Human Genetics (ESHG) Conference
Jun 05, 2019: Cotinga Pharmaceuticals announces initiation of next cohort of phase 1b/2a combination trial of COTI-2 in solid tumors
May 08, 2019: Cotinga Pharmaceuticals releases early interim data of phase 1b/2a combination trial of COTI-2 in solid tumors
Mar 19, 2019: Cotinga Pharmacueticals provides scientific and business update at annual general meeting and announces unit offering
Feb 26, 2019: Cotinga Pharmaceuticals doses first patient in second cohort of phase 1b/2a combination trial of COTI-2 in Solid Tumors
Feb 25, 2019: ArQule announces publication of clinical data with Miransertib in Proteus syndrome
Jan 29, 2019: Cotinga Pharmaceuticals doses cohort 1 patients with combination therapy in phase 1b/2a trial of COTI-2
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
LIST OF TABLES
Number of Products under Development by Stage of Development, H2 2019
Number of Products under Development by Therapy Areas, H2 2019
Number of Products under Development by Indications, H2 2019
Number of Products under Development by Indications, H2 2019 (Contd..1), H2 2019
Number of Products under Development by Companies, H2 2019
Products under Development by Companies, H2 2019
Products under Development by Companies, H2 2019 (Contd..1), H2 2019
Products under Development by Companies, H2 2019 (Contd..2), H2 2019
Products under Development by Companies, H2 2019 (Contd..3), H2 2019
Number of Products by Stage and Mechanism of Actions, H2 2019
Number of Products by Stage and Route of Administration, H2 2019
Number of Products by Stage and Molecule Type, H2 2019
Pipeline by ArQule Inc, H2 2019
Pipeline by AstraZeneca Plc, H2 2019
Pipeline by Bayer AG, H2 2019
Pipeline by Cotinga Pharmaceuticals Inc, H2 2019
Pipeline by Laekna Therapeutics Shanghai Co Ltd, H2 2019
Pipeline by Merck & Co Inc, H2 2019
Pipeline by Novartis AG, H2 2019
Dormant Products, H2 2019
Dormant Products, H2 2019 (Contd..1), H2 2019
Dormant Products, H2 2019 (Contd..2), H2 2019
Dormant Products, H2 2019 (Contd..3), H2 2019
Number of Products under Development by Stage of Development, H2 2019
Number of Products under Development by Therapy Areas, H2 2019
Number of Products under Development by Indications, H2 2019
Number of Products under Development by Indications, H2 2019 (Contd..1), H2 2019
Number of Products under Development by Companies, H2 2019
Products under Development by Companies, H2 2019
Products under Development by Companies, H2 2019 (Contd..1), H2 2019
Products under Development by Companies, H2 2019 (Contd..2), H2 2019
Products under Development by Companies, H2 2019 (Contd..3), H2 2019
Number of Products by Stage and Mechanism of Actions, H2 2019
Number of Products by Stage and Route of Administration, H2 2019
Number of Products by Stage and Molecule Type, H2 2019
Pipeline by ArQule Inc, H2 2019
Pipeline by AstraZeneca Plc, H2 2019
Pipeline by Bayer AG, H2 2019
Pipeline by Cotinga Pharmaceuticals Inc, H2 2019
Pipeline by Laekna Therapeutics Shanghai Co Ltd, H2 2019
Pipeline by Merck & Co Inc, H2 2019
Pipeline by Novartis AG, H2 2019
Dormant Products, H2 2019
Dormant Products, H2 2019 (Contd..1), H2 2019
Dormant Products, H2 2019 (Contd..2), H2 2019
Dormant Products, H2 2019 (Contd..3), H2 2019
LIST OF FIGURES
Number of Products under Development by Stage of Development, H2 2019
Number of Products under Development by Therapy Areas, H2 2019
Number of Products under Development by Top 10 Indications, H2 2019
Number of Products by Stage and Mechanism of Actions, H2 2019
Number of Products by Route of Administration, H2 2019
Number of Products by Molecule Type, H2 2019
COMPANIES MENTIONED
ArQule Inc
AstraZeneca Plc
Bayer AG
Cotinga Pharmaceuticals Inc
Laekna Therapeutics Shanghai Co Ltd
Merck & Co Inc
Novartis AG
Number of Products under Development by Stage of Development, H2 2019
Number of Products under Development by Therapy Areas, H2 2019
Number of Products under Development by Top 10 Indications, H2 2019
Number of Products by Stage and Mechanism of Actions, H2 2019
Number of Products by Route of Administration, H2 2019
Number of Products by Molecule Type, H2 2019
COMPANIES MENTIONED
ArQule Inc
AstraZeneca Plc
Bayer AG
Cotinga Pharmaceuticals Inc
Laekna Therapeutics Shanghai Co Ltd
Merck & Co Inc
Novartis AG
